Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
archives
»
Monthly Archive
» March 2012
March 2012
Abbott: Expect Strong Upside Movement, Both Pre And Post Research Division Spin-Off
Abbott: Expect Strong Upside Movement, Both Pre And Post Research Division Spin-Off
Seeking Alpha
Abbott Laboratories
JNJ
Merck
Pfizer
Sanofi
Watson Pharmaceuticals
Roche may raise bid again if Illumina engaged: source
Roche may raise bid again if Illumina engaged: source
Reuters
Illumina
Roche
M&A
FDA rejects Chelsea's Northera, demands additional study data
FDA rejects Chelsea's Northera, demands additional study data
Fierce Biotech
FDA
Northera
Chelsea Therapeutics
neurogenic orthostatic hypotension
Watson Said to Be in Talks to Buy Swiss Drugmaker Actavis
Watson Said to Be in Talks to Buy Swiss Drugmaker Actavis
Bloomberg
Watson
Actavis
M&A
Will Amylin Be Acquired? What The Wags Say…
Will Amylin Be Acquired? What The Wags Say…
Pharmalot
M&A
Bristol-Myers Squibb
Eli Lilly
AstraZeneca
Astellas extends deal to sell Pfizer's Lipitor in Japan
Astellas extends deal to sell Pfizer's Lipitor in Japan
Reuters
Pfizer
Lipitor
statins
Japan
Astellas
Eli Lilly says psoriasis drug meets goal in study
Eli Lilly says psoriasis drug meets goal in study
Yahoo/AP
psoriasis
Eli Lilly
ixekizumab
Horizon Pharma sues Par Pharma over arthritis drug patent
Horizon Pharma sues Par Pharma over arthritis drug patent
Reuters
Par Pharmaceutical
Horizon Pharma
patents
Duexis
arthritis
FDA adds warnings to Forest Labs' Celexa label
FDA adds warnings to Forest Labs' Celexa label
Reuters
warnings
FDA
Forest Labs
Celexa
antidepressants
Mixed Data on Merck's Vorapaxar
Mixed Data on Merck's Vorapaxar
Yahoo/Zacks.com
Merck
Vorapaxar
TRA-2P
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »